Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV001809107 | SCV002059494 | likely pathogenic | Endometrial carcinoma | 2021-02-12 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002422867 | SCV002719124 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-05-26 | criteria provided, single submitter | clinical testing | The p.S664* pathogenic mutation (also known as c.1991C>A), located in coding exon 4 of the MSH6 gene, results from a C to A substitution at nucleotide position 1991. This changes the amino acid from a serine to a stop codon within coding exon 4. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |